Brequinar
Identification
- Generic Name
- Brequinar
- DrugBank Accession Number
- DB03523
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Brequinar (DB03523)
- Weight
- Average: 375.3675
Monoisotopic: 375.107085139 - Chemical Formula
- C23H15F2NO2
- Synonyms
- Brequinar
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UDihydroorotate dehydrogenase (quinone), mitochondrial Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The risk or severity of adverse effects can be increased when Abatacept is combined with Brequinar. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Brequinar. Adenovirus type 7 vaccine live The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Brequinar. Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Brequinar. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Brequinar. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Brequinar. Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Brequinar. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Brequinar. Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Brequinar. Anthrax immune globulin human The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Brequinar. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Brequinar sodium 49EEF6HRUS 96201-88-6 PZOHOALJQOFNTB-UHFFFAOYSA-M
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenylquinolines. These are heterocyclic compounds containing a quinoline moiety substituted with a phenyl group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Quinolines and derivatives
- Sub Class
- Phenylquinolines
- Direct Parent
- Phenylquinolines
- Alternative Parents
- Quinoline carboxylic acids / Phenylpyridines / Biphenyls and derivatives / Haloquinolines / Pyridinecarboxylic acids / Fluorobenzenes / Methylpyridines / Aryl fluorides / Heteroaromatic compounds / Azacyclic compounds show 8 more
- Substituents
- 2-phenylpyridine / Aromatic heteropolycyclic compound / Aryl fluoride / Aryl halide / Azacycle / Benzenoid / Biphenyl / Carboxylic acid / Carboxylic acid derivative / Fluorobenzene show 20 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 5XL19F49H6
- CAS number
- 96187-53-0
- InChI Key
- PHEZJEYUWHETKO-UHFFFAOYSA-N
- InChI
- InChI=1S/C23H15F2NO2/c1-13-21(23(27)28)18-12-16(24)10-11-20(18)26-22(13)15-8-6-14(7-9-15)17-4-2-3-5-19(17)25/h2-12H,1H3,(H,27,28)
- IUPAC Name
- 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid
- SMILES
- CC1=C(N=C2C=CC(F)=CC2=C1C(O)=O)C1=CC=C(C=C1)C1=CC=CC=C1F
References
- General References
- Not Available
- External Links
- PubChem Compound
- 57030
- PubChem Substance
- 46504783
- ChemSpider
- 51422
- BindingDB
- 15339
- ChEMBL
- CHEMBL38434
- ZINC
- ZINC000001587011
- PDBe Ligand
- BRF
- Wikipedia
- Brequinar
- PDB Entries
- 1uuo
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Coronavirus Disease 2019 (COVID‑19) / Covid 19 Infection 1 1, 2 Completed Treatment Acute Myeloid Leukemia (AML) 1 1, 2 Completed Treatment Coronavirus Disease 2019 (COVID‑19) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.000539 mg/mL ALOGPS logP 5.05 ALOGPS logP 6.27 ChemAxon logS -5.8 ALOGPS pKa (Strongest Acidic) 3.38 ChemAxon pKa (Strongest Basic) 0.75 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 50.19 Å2 ChemAxon Rotatable Bond Count 3 ChemAxon Refractivity 102.61 m3·mol-1 ChemAxon Polarizability 38.43 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9745 Caco-2 permeable + 0.7523 P-glycoprotein substrate Non-substrate 0.7193 P-glycoprotein inhibitor I Non-inhibitor 0.8927 P-glycoprotein inhibitor II Non-inhibitor 0.9706 Renal organic cation transporter Non-inhibitor 0.9035 CYP450 2C9 substrate Non-substrate 0.7659 CYP450 2D6 substrate Non-substrate 0.8467 CYP450 3A4 substrate Non-substrate 0.6366 CYP450 1A2 substrate Non-inhibitor 0.6456 CYP450 2C9 inhibitor Inhibitor 0.5743 CYP450 2D6 inhibitor Non-inhibitor 0.9679 CYP450 2C19 inhibitor Non-inhibitor 0.8437 CYP450 3A4 inhibitor Non-inhibitor 0.9302 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9268 Ames test Non AMES toxic 0.8381 Carcinogenicity Non-carcinogens 0.8718 Biodegradation Not ready biodegradable 0.9922 Rat acute toxicity 2.6182 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9898 hERG inhibition (predictor II) Non-inhibitor 0.8891
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Ubiquinone binding
- Specific Function
- Catalyzes the conversion of dihydroorotate to orotate with quinone as electron acceptor.
- Gene Name
- DHODH
- Uniprot ID
- Q02127
- Uniprot Name
- Dihydroorotate dehydrogenase (quinone), mitochondrial
- Molecular Weight
- 42866.93 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Drug created on June 13, 2005 13:24 / Updated on February 21, 2021 18:51